Use of INTERCEPT Platelets at a US Tertiary Care, Academic Medical Center
Use of INTERCEPT Platelets at a US Tertiary Care, Academic Medical Center
2 PagesCase Study: Use of INTERCEPT Platelets at a US Tertiary Care, Academic Medical Center 1 INTERCEPT ® Blood System for Platelets Pathogen Reduction System The following case study highlights the use of INTERCEPT pathogen reduced products at one of the country’s largest health care providers which supports more than 1,100 patient beds. This US hospital system specializes in cancer care, women’s health, and houses a Level I trauma center and Level III neonatal intensive care unit. The Challenge Industry concern has recently been heightened about the risk of bacterial contamination in platelet components. The release of the FDA guidance 2 represents the ongoing effort to address bacterial transfusion-transmitted infections and related sepsis risk. The guidance indicates that platelet
